5-氟尿嘧啶血药浓度对替吉奥联合紫杉醇治疗晚期胃癌疗效的评估价值

发布时间：2018-08-02 08:46

【摘要】：目的:探讨5-氟尿嘧啶(5-FU)血药浓度与替吉奥联合紫杉醇治疗晚期胃癌患者的疗效和安全性之间的关系。方法:选取78例接受替吉奥联合紫杉醇治疗的晚期胃癌患者,于每一个化疗周期监测5-FU血药浓度。分析5-FU血药浓度与疗效和安全性的关系。结果:78例患者不同化疗周期5-FU的中位血药浓度为150μg/L,据此将患者分为A组(≥150μg/L,40例)和B组(150μg/L,38例)。A组有效率及疾病控制率均高于B组(50.0%vs 18.4%,82.5%vs 65.8%,P均0.05)。A组骨髓抑制及口腔炎较B组严重(P均0.05);但2组间恶心、呕吐及腹泻的严重程度差异无统计学意义(P均0.05)。结论:5-FU血药浓度≥150μg/L的晚期胃癌患者采用替吉奥联合紫杉醇治疗有更好的生存获益,但会增加骨髓抑制及口腔炎等不良反应的严重程度。
[Abstract]:Aim: to investigate the relationship between the serum concentration of 5 fluorouracil (5-FU) and the efficacy and safety of tigor combined with paclitaxel in the treatment of advanced gastric cancer. Methods: 78 patients with advanced gastric cancer treated with teguir combined with paclitaxel were selected to monitor the serum concentration of 5-FU in each chemotherapy cycle. To analyze the relationship between serum concentration of 5-FU and efficacy and safety. Results the median blood concentration of 5-FU in 78 patients with different chemotherapy cycles was 150 渭 g / L, according to which the patients were divided into two groups: group A (40 cases 鈮，

本文编号：2158875